Slingshot members are tracking this event:

Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details enrolled the first patient in the STRIDE-1 (Symptom Treatment in Resistant Depression 1) study, a Phase 3 trial evaluating the efficacy and safety of AXS-05 for the treatment of treatment resistant depression (TRD). AXS-05 is an innovative oral therapeutic, with activity at several key neurotransmitter systems, being developed for the treatment of CNS disorders. AXS-05 combines mechanisms of action of several distinct antidepressant drug classes.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Axs-05, Treatment Resistant Depression, Stride-1, Trd, Major Depressive Disorder, Antidepressant, Bupropion